Middle Peak Medical, a Munich, Germany-based development-stage medical device company, raised an additional $3m in a second closing of its over-subscribed Series A financing.
that will commercialize a novel technology for treating mitral valve disease, which now totals approximately $11M.
Backers included BioMedInvest II LP and Edwards LifeSciences (NYSE: EW), Wellington Partners and Seventure Partners, which added to their investment from the first close.
The company intends to use the funds to further develop its technology for treating mitral valve disease.
Led by Michael D. Lesh, MD, CEO and co-founder, Middle Peak focuses on developing technology that has application in both minimally invasive cardiac surgery, and catheter-based percutaneous intervention.
The company has R&D operations in Palo Alto, and its clinical and regulatory operations in Germany.
FinSMEs
28/10/2013
Related News
27/10/2013: Middle Peak Medical Raises $8.5M in Series A Financing